Immunic Inc (IMUX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $114.82M
Last updated: Nov 17, 2026 at 4:16 PM ET
Immunic Inc (IMUX) Statistics
Immunic (IMUX) has a market cap of $114.82M. Revenue fell 100.00% over the last 12 months from the 12 months before. It holds $131.96M more cash than debt, 114.93% of its market cap.
Total Valuation
| Market Cap | $114.82M |
|---|---|
| Latest price (Nov 17, 2026) | $7.33 |
Key Dates
The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 13, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 5.84% over 52 weeks and trades 13.46% below its 50-day average.
| Beta (1Y) | 1.55 |
|---|---|
| 52-Week Change | -5.84% |
| 1-Month Change | +4.86% |
| 3-Month Change | -55.44% |
| 6-Month Change | -36.81% |
| 5-Year Change | -91.94% |
| 10-Year Change | -99.65% |
| Total Return (1Y) | -5.84% |
| Total Return (3Y CAGR) | -11.57% |
| Total Return (5Y CAGR) | -39.13% |
| Return vs SPY (1Y) | -15.11% |
| Max Drawdown (1Y) | -60.59% |
| Max Drawdown (3Y) | -73.84% |
| Sharpe Ratio (1Y) | -0.04 |
| Correlation with SPY (1Y) | 0.26 |
| 50-Day Average | $8.47 |
| 200-Day Average | $11.57 |
| 52-Week Range | $5.06 to $17.43 |
| RSI (14 Days) | 41.9 |
| Average Volume (20 Days) | 248.99K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 4.28x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 4.28x |
|---|---|
| Quick Ratio | 4.28x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -122.80% and return on assets is -94.04% over the last 12 months.
| Return on Equity (ROE) | -122.80% |
|---|---|
| Return on Assets (ROA) | -94.04% |
Scores
IMUX has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$42.00K |
| Operating Income | -$135.26M |
| Pretax Income | -$128.30M |
| Net Income | -$128.30M |
| Reported EPS (TTM) | -$2.99 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 76.58% of the $136.42M in total assets.
| Cash and Equivalents | $131.96M |
|---|---|
| Total Debt | $0 |
| Net Cash | $131.96M |
| Net Cash Per Share | $3.08 |
| Working Capital | $103.54M |
| Shareholder Equity | $104.47M |
| Book Value Per Share | $2.44 |
| Total Assets | $136.42M |
| Total Liabilities | $31.95M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $366.00K of capital spending, operating cash flow left -$96.33M of free cash flow.
| Operating Cash Flow | -$95.97M |
|---|---|
| Capital Expenditures | $366.00K |
| Free Cash Flow | -$96.33M |
| FCF Per Share | -$7.06 |
| Depreciation and Amortization | $147.00K |
Trailing 12 months through Sep 30, 2026.
Dividends and Yields
IMUX does not pay a dividend. Its free cash flow yield is -30.71%.
| FCF Yield | -30.71% |
|---|---|
| Buyback Yield | -59.78% |
| Shareholder Yield | -59.78% |
Stock Splits
The last split was a 1-for-10 reverse split on Apr 27, 2026.
| Last Split Date | Apr 27, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:10 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About IMUX
What is IMUX's market cap?
Immunic has a market cap of $114.82M.
How many shares of IMUX are outstanding?
Immunic has 42.80M shares outstanding.
Does IMUX pay a dividend?
No. Immunic does not pay a dividend.
How much debt does IMUX have?
Immunic has $0 of total debt and $131.96M of cash and equivalents, a net cash position of $131.96M.
IMUX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors